EA201790314A1 - Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор - Google Patents

Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор

Info

Publication number
EA201790314A1
EA201790314A1 EA201790314A EA201790314A EA201790314A1 EA 201790314 A1 EA201790314 A1 EA 201790314A1 EA 201790314 A EA201790314 A EA 201790314A EA 201790314 A EA201790314 A EA 201790314A EA 201790314 A1 EA201790314 A1 EA 201790314A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
epsilon
gamma
antibodies directed
new antibodies
Prior art date
Application number
EA201790314A
Other languages
English (en)
Other versions
EA035269B1 (ru
Inventor
Анна Карле
Каролин Диренбергер
Петер Сондерман
Мартина Мюллер
Николе Рит
Томас Поль
Original Assignee
Зуппремоль Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зуппремоль Гмбх filed Critical Зуппремоль Гмбх
Publication of EA201790314A1 publication Critical patent/EA201790314A1/ru
Publication of EA035269B1 publication Critical patent/EA035269B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В данном документе раскрыты распознающие молекулы, которые связываются с помощью первого связывающего домена с Fc-эпсилон-рецептором (FcεR) и с помощью второго связывающего домена с Fc-гамма-рецептором IIB (FcγRIIB), a также пути применения таких распознающих молекул.
EA201790314A 2014-08-13 2015-08-13 АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР EA035269B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14002825 2014-08-13
PCT/EP2015/068667 WO2016023985A1 (en) 2014-08-13 2015-08-13 Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Publications (2)

Publication Number Publication Date
EA201790314A1 true EA201790314A1 (ru) 2017-06-30
EA035269B1 EA035269B1 (ru) 2020-05-22

Family

ID=51355407

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790314A EA035269B1 (ru) 2014-08-13 2015-08-13 АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР

Country Status (19)

Country Link
US (1) US10730946B2 (ru)
EP (1) EP3180358B1 (ru)
JP (1) JP6808611B2 (ru)
KR (1) KR102424169B1 (ru)
CN (1) CN106795223B (ru)
AR (1) AR101555A1 (ru)
AU (1) AU2015303142B2 (ru)
BR (1) BR112017002755B1 (ru)
CA (1) CA2957850A1 (ru)
CL (1) CL2017000360A1 (ru)
CO (1) CO2017001384A2 (ru)
EA (1) EA035269B1 (ru)
ES (1) ES2802176T3 (ru)
IL (1) IL250569B (ru)
MX (1) MX2017001895A (ru)
MY (1) MY180940A (ru)
SG (1) SG11201701028SA (ru)
TW (1) TWI713464B (ru)
WO (1) WO2016023985A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
ES2802176T3 (es) 2014-08-13 2021-01-15 Suppremol Gmbh Nuevos anticuerpos dirigidos contra el receptor IIB de Fc gamma y el receptor de Fc épsilon
WO2018036947A1 (en) * 2016-08-22 2018-03-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inhibiting biological responses induced by a receptor that uses pi3k to signal in a cell
MX2022004073A (es) * 2019-10-01 2022-07-12 Epsilogen Ltd Anticuerpo hibrido.
CN113214392B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体ky031、制备方法及用途
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487480B1 (en) * 2001-05-01 2015-10-07 The Regents of The University of California Fusion molecules for treatment of immune diseases
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2005051999A2 (en) 2003-11-26 2005-06-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substance binding human igg fc receptor iib
SG173322A1 (en) * 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
CA2577405A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
SG195073A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
ES2802176T3 (es) 2014-08-13 2021-01-15 Suppremol Gmbh Nuevos anticuerpos dirigidos contra el receptor IIB de Fc gamma y el receptor de Fc épsilon

Also Published As

Publication number Publication date
US20170226208A1 (en) 2017-08-10
MY180940A (en) 2020-12-14
WO2016023985A1 (en) 2016-02-18
US10730946B2 (en) 2020-08-04
KR20170041250A (ko) 2017-04-14
JP6808611B2 (ja) 2021-01-06
CA2957850A1 (en) 2016-02-18
KR102424169B1 (ko) 2022-07-25
EP3180358B1 (en) 2020-04-01
TW201629099A (zh) 2016-08-16
AR101555A1 (es) 2016-12-28
EP3180358A1 (en) 2017-06-21
JP2017529832A (ja) 2017-10-12
BR112017002755A2 (pt) 2017-12-19
CL2017000360A1 (es) 2017-07-14
EA035269B1 (ru) 2020-05-22
CN106795223A (zh) 2017-05-31
IL250569B (en) 2021-05-31
CN106795223B (zh) 2021-05-04
TWI713464B (zh) 2020-12-21
SG11201701028SA (en) 2017-03-30
IL250569A0 (en) 2017-03-30
AU2015303142A1 (en) 2017-03-02
MX2017001895A (es) 2017-08-28
ES2802176T3 (es) 2021-01-15
CO2017001384A2 (es) 2017-05-10
BR112017002755B1 (pt) 2023-12-26
AU2015303142B2 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
EA201790314A1 (ru) Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2017006530A (es) Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016022841A2 (pt) cadeia j modificada
EA201790173A1 (ru) Антитела, связывающие axl
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
PH12016501366A1 (en) Novel anti-baff antibodies
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM